Alimera Sciences Limited
08018355
Some Concerns
- Negative net worth (-10)
- Loss before tax (-10)
- Going concern doubt noted in accounts (-10)
Details
Compliance
Accounts
Confirmation statement
Industry
Officers
director · Since 01/01/2013
MANAGING DIRECTOR
BRITISH · ENGLAND · Age 61
Also on 1 other board
director · Since 12/12/2024
CHIEF FINANCIAL OFFICER OF ANI PHARMACEU
AMERICAN · UNITED STATES · Age 56
director · Since 12/12/2024
CEO AND PRESIDENT OF ANI PHARMACEUTICALS
INDIAN · UNITED STATES · Age 48
Persons with Significant Control
Ani Pharmaceuticals, Inc.
210 Main Street West, Baudette, 56623
Reg: 3379943 · Us (Delaware) · Corporate
Notified 16/09/2024
Former PSCs
Alimera Sciences, Inc.
Ceased 16/09/2024
Charges0 outstanding
HERCULES TECHNOLOGY GROWTH CAPITAL, INC
HERCULES TECHNOLOGY GROWTH CAPITAL,INC.
SILICON VALLEY BANK
CompanyRankvs 814960+ SIC 82990 peers50
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Going concern doubt: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Going Concern Doubt
we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going co
Key FinancialsYear ending 31/12/2024
Turnover
£18.6M
Annual revenue
Net Worth
-£34.7M
Balance sheet strength
Cash
£1.2M
Cash in the bank
Profit Before Tax
-£15.2M
Bottom line earnings
Net Current Assets
£7.0M
Working capital
Current Assets
£17.6M
Current Liabilities
£10.6M
Fixed Assets
£36.7M
Debtors
£15.8M
Cost of Sales
£1.3M
Gross Profit
£17.3M
Admin Expenses
£27.2M
Operating Profit
-£9.9M
Profit After Tax
-£15.1M
Balance Sheet
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2024 | 1.66 | +£0 |
| 2024 | 1.66 | — |
Derived from filed accounts. Not audited figures.